Science
Alireza Mansouri: Intracranial B7-H3 CAR-T Shows Promise in Recurrent Glioblastoma Phase 1 Trial
Alireza Mansouri/ LinkedIn

Alireza Mansouri: Intracranial B7-H3 CAR-T Shows Promise in Recurrent Glioblastoma Phase 1 Trial

Alireza Mansouri, Associate Professor at Penn State Health, shared on LinkedIn:

“Important Phase 1 data now published in Nature Medicine: intracranial delivery of autologous B7-H3-targeting CAR-T cells (TX103) in recurrent glioblastoma.

Highlights:

  • Open-label 3+3 dose-escalation trial
  • No dose-limiting toxicities observed
  • Disease control (stable disease or better) in 8 of 14 patients with measurable disease, including one complete response sustained at last follow-up
  • 12-month overall survival rate: 66.7%
  • Median overall survival: 19.1 months from first infusion
  • Marked CAR expansion and cytokine release in CSF with minimal peripheral activity

These findings support the feasibility and encouraging activity of local CAR-T delivery in rGBM and the selection of a recommended Phase 2 dose.”

Title: Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial

Authors: Yang Zhang, Xiaohan Chi, Rui Feng, Na Xian, Na Huang, Shengjun Sun, Xiaobin Zhao, Peng Zhang, Kang Liu, Yiwen Ma, Yu Zhang, Kangna Zhang, Sihui Wang, Xianzhen Chen, Jindong Zhang, Wuqing Huang, Baozhu Huang, Tina Tianjiao Su, Jacky Yeung, Jianwei He, Lieping Chen, Nan Ji, Gangxiong Huang

Read the Full Article

Alireza Mansouri

 

Other articles about Glioblastoma on OncoDaily.

Alireza Mansouri Baozhu Huang cancer CAR-T Gangxiong Huang glioblastoma Jacky Yeung Jianwei He Jindong Zhang Kang Liu Kangna Zhang Lieping Chen Na Huang Na Xian Nan Ji Nature Medicine OncoDaily Oncology Peng Zhang Rui Feng Shengjun Sun Sihui Wang Tina Tianjiao Su Wuqing Huang Xianzhen Chen Xiaobin Zhao Xiaohan Chi Yang Zhang Yiwen Ma Yu Zhang